Dermatomyositis and Cosmetic Surgery: Heliotrope Rash, Gottron Papules, Calcinosis, Cancer Screening, Lung Disease, and Steroids

She is 52 and came in about her eyelids. Over the past four months her upper lids have become puffy and taken on a faint violet tint that concealer turns gray rather than hiding. She has read about blepharoplasty and assumes she has finally inherited her mother's heavy lids. Almost as an aside, she mentions that the skin over her knuckles has become rough and pink, that her chest and the back of her neck itch after a morning outdoors, and that she has been sitting down to dry her hair because her arms get tired. She thinks the tiredness is age. She thinks the knuckles are dish soap.

A good surgeon hears that history and puts the scalpel away. Violet, swollen upper eyelids, rough red patches over the knuckles, a rash on sun-exposed skin of the chest and upper back, and new weakness in the shoulders is close to a textbook description of dermatomyositis. It is a rare disease, but it is one that tends to present on precisely the parts of the body that bring people to cosmetic practices, and it carries consequences well beyond the skin: muscle weakness that can reach the throat and the breathing muscles, lung scarring that can move quickly, and in adults, a real association with cancer. This piece covers how dermatomyositis interacts with cosmetic surgery and injectables, what has to happen before anything elective, and where the genuine opportunities for help lie once the disease is under control.

Dermatomyositis and cosmetic surgery: what the disease is and why it shows up on the face first

The short answer: dermatomyositis is an autoimmune disease that inflames the skin and the muscles, and because the rash often appears on the eyelids, cheeks, chest, and hands before the weakness is obvious, it is regularly mistaken for an aesthetic complaint.

Dermatomyositis belongs to a family called the idiopathic inflammatory myopathies, conditions in which the immune system attacks muscle. What sets dermatomyositis apart is the skin. The immune injury in this disease targets small blood vessels in the skin and muscle, which produces a set of rashes distinctive enough that dermatologists can often suspect the diagnosis from across the room. The disease is uncommon, with incidence estimates in the range of a few new cases per 100,000 people per year, and it affects women roughly twice as often as men. In adults it most often begins between the ages of 40 and 60, exactly the decade when many people begin thinking about eyelid surgery, facial rejuvenation, and body contouring. A separate juvenile form begins in childhood, and adults who had it as children carry their own set of long-term issues, discussed below.

The classic skin findings are worth knowing by name, because each one can masquerade as something cosmetic:

• Heliotrope rash. A violet or dusky pink discoloration of the upper eyelids, often with swelling. It can look like puffy lids, allergic swelling, or the beginning of malar mounds and festoons.
• Gottron papules and Gottron sign. Raised pink to violet bumps or flat scaly patches over the knuckles, and sometimes over the elbows and knees. They are often dismissed as eczema or dry skin.
• The V sign and shawl sign. Red to violet discoloration across the front of the neck and upper chest, or across the upper back and shoulders, in a pattern that follows sun exposure. It is easy to mistake for sun damage or rosacea spreading down the neck.
• Facial redness. Redness across the cheeks and forehead that can resemble rosacea, the kind of complaint that brings people in for vascular laser treatment for facial redness.
• Nail fold changes. Ragged, overgrown cuticles and visible enlarged capillaries at the base of the nails.
• Mechanic's hands. Cracked, thickened skin along the sides of the fingers, most often in a subtype linked to lung disease.
• Scalp involvement. A scaly, intensely itchy scalp, sometimes with hair thinning.

Two features help separate dermatomyositis from the conditions it imitates. First, it itches, often fiercely, which is unusual for lupus and for plain sun damage. Second, it is photosensitive: ultraviolet light makes the rash flare, which is why it concentrates on the face, the V of the neck, and the backs of the hands.

Not everyone with the rash has obvious weakness. A subtype called clinically amyopathic dermatomyositis produces the skin disease with little or no measurable muscle involvement. That is precisely the patient most likely to land in a cosmetic office, because there is no limp, no difficulty climbing stairs, and nothing that feels like a medical illness. It is also not a benign subtype. Some of the most serious lung complications occur in patients whose muscles seem fine.

The broader framework for any autoimmune condition before elective surgery is covered in the piece on cosmetic surgery with autoimmune disease. Dermatomyositis deserves its own treatment because of three features that piece does not dwell on: the cancer association, the lungs, and the swallowing muscles.

The cancer question: why a new diagnosis comes before any elective plan

The short answer: in adults, dermatomyositis is associated with an increased risk of cancer, concentrated in the few years around diagnosis, so a person newly diagnosed should complete age-appropriate and disease-specific cancer screening before any elective cosmetic procedure is scheduled.

This is the single most important fact in this article, and it is the one most likely to be missed when the presenting complaint is cosmetic. Large population studies have consistently found that adults with dermatomyositis have a higher rate of cancer than the general population, with frequently cited estimates that somewhere around 15 to 25 percent of adult patients are diagnosed with a cancer in the period surrounding their dermatomyositis diagnosis. The risk is highest in the year or two before and the first three years after the skin and muscle symptoms appear, and it declines after that. In some cases dermatomyositis is effectively an early warning sign: the immune response that attacks the skin and muscle appears to be triggered, at least in part, by the tumor.

The cancers most often linked to dermatomyositis include ovarian, lung, pancreatic, stomach, colorectal, and breast cancers, along with non-Hodgkin lymphoma. In people of East and Southeast Asian ancestry, nasopharyngeal cancer is a notable association. Risk is higher in older patients, in men, in patients with skin ulceration or rapidly progressive disease, and in those who test positive for certain myositis-specific antibodies, particularly anti-TIF1-gamma and, to a lesser extent, anti-NXP2.

In 2023 the International Myositis Assessment and Clinical Studies Group (IMACS) published the first international consensus guidance on cancer screening in myositis. It sorts patients into risk categories based on their subtype, antibodies, and clinical features, and recommends a screening program to match. For a higher-risk adult with dermatomyositis, that typically goes well beyond routine checks and may include CT imaging of the chest, abdomen, and pelvis, pelvic ultrasound and blood tests aimed at ovarian cancer in women, and in some cases PET scanning or endoscopy, with repeat screening over the following years.

For cosmetic surgery, this has concrete implications:

• Breast surgery. Anyone with dermatomyositis considering augmentation, reduction, or a lift should have breast imaging that is fully up to date before surgery, and a surgeon who sends reduction tissue to pathology. The reasoning parallels the advice in the piece on family history of breast cancer and cosmetic breast surgery.
• Abdominal procedures. Because ovarian cancer is one of the more strongly associated tumors, a woman with recent-onset dermatomyositis who wants a tummy tuck should have completed pelvic screening first. A new or unexplained abdominal fullness should not be assumed to be loose skin and fat.
• Unexplained weight loss. Losing weight without trying is a warning sign in this disease, not a head start on body contouring.
• Timing. Most specialists would be uncomfortable with elective surgery in the first year or two after diagnosis, both because screening is still in progress and because the disease itself is usually still being brought under control.

None of this is a reason for alarm in someone who has had dermatomyositis for ten years with a clean screening history. It is a reason for real caution in someone whose symptoms began this year, and an absolute reason not to treat a brand-new heliotrope rash as an eyelid problem. Patients who have already been through cancer treatment will find the timing questions covered in the piece on cosmetic surgery after chemotherapy.

Lungs, swallowing, and the heart: what the anesthesiologist needs to know

The short answer: dermatomyositis can scar the lungs, weaken the muscles of swallowing and breathing, and occasionally inflame the heart, so pulmonary function testing, a swallowing assessment, and a heart evaluation should be part of the workup before a general anesthetic.

Interstitial lung disease, an inflammatory scarring of the lung tissue, is the leading cause of serious illness and death in dermatomyositis. Estimates of how often it occurs vary widely by population and by how hard doctors look, but it is common enough that most myositis specialists screen every patient with lung function tests and a high-resolution CT scan. Certain antibodies predict it. The anti-synthetase antibodies, of which anti-Jo-1 is the most common, are linked with lung disease, arthritis, mechanic's hands, and Raynaud phenomenon. The anti-MDA5 antibody, which is more common in East Asian populations, is associated with a form of lung disease that can progress over weeks rather than years, often in patients with minimal muscle weakness and with distinctive skin ulcers and painful palm papules. A patient with anti-MDA5 dermatomyositis is not a candidate for elective surgery until a specialist says the lungs are stable, and that may take a long time.

The swallowing issue is less well known and directly relevant to anesthesia. Dermatomyositis can weaken the muscles of the throat and upper esophagus, producing difficulty swallowing, a sense of food sticking, nasal regurgitation, or coughing during meals. That raises the risk of aspiration, meaning inhaling stomach contents or saliva into the lungs, both during sedation and in the hours after surgery. A patient who mentions any trouble swallowing should have a formal swallowing evaluation before an elective anesthetic. Weakness of the breathing muscles, though uncommon, compounds the problem by making it harder to cough and clear the airway after surgery.

The heart is involved less often, but involvement can include inflammation of the heart muscle and disturbances of the heart's rhythm, sometimes without symptoms. An electrocardiogram is a minimum before surgery, and many anesthesiologists will want an echocardiogram or a cardiology review, particularly in patients with active disease or abnormal blood markers of muscle injury. The general logic of preoperative testing before cosmetic surgery applies with more force here.

The anesthetic plan itself raises specific questions:

• Muscle relaxants. People with inflammatory muscle disease may respond unpredictably to neuromuscular blocking drugs, and succinylcholine is generally avoided in patients with myopathies. The anesthesiologist will usually dose carefully and monitor the depth of muscle relaxation throughout.
• Choice of technique. For smaller procedures, local anesthesia or light sedation avoids many of these issues. For larger ones, the trade-offs are discussed in the piece on anesthesia choice and the operative plan.
• Procedure length. Shorter operations, staged where necessary, reduce cumulative anesthetic exposure and time spent immobile.
• Setting. A patient with lung involvement, swallowing weakness, or heart findings belongs in a hospital or accredited facility with overnight monitoring, not an office suite with same-day discharge.

The parallel with other neuromuscular conditions is useful. The piece on myasthenia gravis and cosmetic surgery covers a different disease, one of the nerve-muscle junction rather than the muscle itself, but many of the same anesthetic precautions apply. Likewise, patients with lung scarring will recognize some of the questions raised in the piece on COPD and cosmetic surgery, even though the underlying disease is different.

Steroids, immunosuppressants, and IVIG: the medication plan around surgery

The short answer: most people with dermatomyositis take steroids plus at least one other immune-suppressing drug, and each needs a deliberate decision about whether to continue, adjust, or time around surgery, made jointly by the surgeon and the treating specialist.

Treatment usually begins with high-dose glucocorticoids such as prednisone, followed by a steroid-sparing agent so the steroid dose can be reduced. Common choices include methotrexate, azathioprine, and mycophenolate. Intravenous immunoglobulin (IVIG) is used for resistant disease and for severe swallowing involvement, and in 2021 the FDA approved an IVIG product specifically for adult dermatomyositis, the first approval of its kind for the disease. Rituximab is used in refractory cases. Hydroxychloroquine is sometimes prescribed for the skin disease, although people with dermatomyositis appear to develop drug rashes from it more often than people with lupus do. Calcineurin inhibitors and, increasingly, JAK inhibitors are used in difficult cases, particularly for the skin and for anti-MDA5 lung disease, mostly off label.

Each of these matters for surgery:

• Long-term steroids. Steroids slow wound healing, thin the skin, raise infection risk, and raise blood sugar. Anyone on steroids for more than a few weeks may also have a suppressed adrenal response and need extra steroid coverage on the day of surgery, the same issue discussed in the piece on Addison's disease and stress-dose steroids. This is separate from the short steroid courses some surgeons prescribe for swelling after plastic surgery, which should be coordinated with the patient's baseline dose rather than stacked on top of it unknowingly.
• Steroid myopathy. High-dose steroids can themselves cause muscle weakness. A patient who is getting weaker on treatment may be having a flare or a drug side effect, and that question should be answered before an operation, not after.
• Steroid body changes. Weight gain, a rounder face, and fat over the upper back are common on high doses. They often improve as the dose comes down, so liposuction or facial procedures aimed at steroid-related changes are usually wiser to defer until the dose has been low and stable for months.
• Methotrexate, azathioprine, and mycophenolate. For orthopedic surgery in rheumatic disease, the 2022 American College of Rheumatology and American Association of Hip and Knee Surgeons guideline generally favors continuing methotrexate and certain other conventional drugs rather than stopping them, because the risk of a flare outweighs the modest effect on healing. That guideline was not written for dermatomyositis or cosmetic surgery, but it is the reference most surgeons borrow, and any change should be decided by the prescribing specialist.
• Biologics and IVIG. Infusions are usually scheduled so that surgery falls toward the end of a dosing interval. IVIG also carries a small risk of blood clots, which is relevant to procedures, like tummy tucks and long body contouring cases, that already carry a meaningful clot risk. The general principles are in the piece on blood clots after plastic surgery.

Immunosuppressed patients heal more slowly and are more vulnerable to infection and incisions that separate. Surgeons who know this tend to plan smaller operations, longer suture times, and closer follow-up. The risks and warning signs are covered in the piece on wound dehiscence after cosmetic surgery.

"Dermatomyositis puts its first signs on the eyelids, the cheeks, the chest, and the knuckles, which is where cosmetic medicine looks. The surgeon who sees a violet eyelid and asks about the patient's shoulders, swallowing, and cancer screening has done more for her than any blepharoplasty could."

Calcinosis, lasers, injectables, and sun: what can actually be done

The short answer: once dermatomyositis is controlled and screening is complete, many cosmetic treatments are reasonable, but sun exposure is a genuine flare trigger, calcium deposits are hard to treat, and anything injected into the face or neck should be planned around the disease's effect on muscle and swallowing.

Calcinosis. Some people with dermatomyositis develop calcinosis cutis, hard deposits of calcium in the skin and the tissue beneath it. It is much more common in the juvenile form than in adults, and in adults it is associated with the anti-NXP2 antibody. Deposits typically form over pressure points such as the elbows, knees, fingers, and buttocks, and they can ulcerate, drain chalky material, and become infected. No medication reliably dissolves established calcinosis, although several are tried. Surgical excision of individual painful or ulcerated deposits is a legitimate option and can help a great deal, but the skin over them heals poorly, recurrence is possible, and the operation should be done by a surgeon who has treated calcinosis before. Liposuction or fat grafting through an area of known calcinosis is generally a poor idea.

Fat loss in juvenile dermatomyositis. Adults who had the juvenile form may have acquired lipodystrophy, a gradual loss of fat, often from the face, arms, or legs, sometimes accompanied by insulin resistance, high triglycerides, or fatty liver. These patients may seek fillers or fat grafting to restore facial volume. That can be reasonable, but the metabolic side of lipodystrophy needs to be checked first, and the volume of fat available for grafting may be limited.

Sun, lasers, and light. Ultraviolet light flares dermatomyositis. Every person with the disease should already be using broad-spectrum sunscreen every day, wearing hats and protective clothing, and avoiding midday sun, and a cosmetic plan should be built around that. Light-based treatments are less clear-cut. There is limited evidence on how intense pulsed light, vascular lasers, or resurfacing lasers affect dermatomyositis skin, and the responsible approach is caution: treat only quiet skin, start with a test spot, and avoid aggressive resurfacing in areas with active rash. The differences between treatments are covered in the pieces on lasers for sun spots and pigmentation and ablative versus non-ablative laser resurfacing. Some patients have long-lasting discoloration across the chest from old disease, a mottled mix of light, dark, and red known as poikiloderma, and cautious, staged treatment of the décolletage can help once the disease is inactive.

The eyelids. A heliotrope rash is not a reason for blepharoplasty, and operating on swollen, inflamed lids can produce a poor result as the swelling settles and the disease is treated. Once the disease has been quiet for a meaningful period, eyelid surgery for genuine excess skin is reasonable. Any drooping of the lid itself should be distinguished from muscle weakness, a question addressed in the piece on eyelid ptosis versus blepharoplasty.

Neurotoxins. Botulinum toxin weakens muscle on purpose, and in someone with a muscle disease that deserves extra thought. Small doses in the upper face are unlikely to cause harm in a patient whose disease is controlled, but injections in the neck, such as treatments for platysma bands, carry a known risk of affecting swallowing even in healthy people, and in someone who already has throat muscle weakness that risk is not worth taking. Patients combining treatments should read the piece on Botox and filler at one visit with that caveat in mind.

Fillers. Hyaluronic acid fillers are the more conservative choice for someone with an autoimmune disease, mainly because they can be dissolved if a problem develops. Biostimulatory fillers, which work by provoking an inflammatory tissue response, are harder to justify in active autoimmune disease. The trade-offs are covered in the piece on biostimulatory fillers versus hyaluronic acid.

The hands. Gottron papules, nail fold changes, and mechanic's hands make the hands a common source of distress. Many of these changes fade as the disease is treated. Cosmetic treatment of the hands, discussed in the piece on hand rejuvenation, should wait until then, and patients who also have Raynaud phenomenon should read the separate piece on Raynaud's and cosmetic surgery before any procedure that affects blood flow to the fingers.

Body procedures. For someone whose disease is in long remission, with complete screening, normal lung and heart testing, and no swallowing problems, body contouring such as liposuction, tummy tucks, and breast surgery can be reasonable. The usual adjustments apply: a lower medication burden on the day of surgery, an experienced anesthesia team, and a recovery plan that accounts for reduced strength. Proximal weakness in particular makes getting out of a low chair or bed difficult after an abdominal operation, and that should be anticipated with a raised seat, help at home, and physical therapy if needed.

For anyone uncertain whether a surgeon is taking the disease seriously enough, a second consultation with a surgeon who has worked alongside rheumatologists is worth the time. The same approach applies to other autoimmune skin diseases covered on this site, including sarcoidosis.

The honest summary

Dermatomyositis does not rule out cosmetic surgery or injectables, but it changes what comes first. Its rash appears on the eyelids, cheeks, neck, chest, and knuckles, so it is often mistaken for an aesthetic problem: violet, puffy upper lids that look like they need blepharoplasty, a red chest that looks like sun damage, rough knuckles that look like dry skin. Anyone with that pattern, especially with new tiredness in the shoulders or hips, trouble swallowing, or a cough, needs a diagnosis before a procedure. In adults the disease carries a real association with cancer, concentrated in the first few years, so screening must be complete before anything elective. The lungs, the swallowing muscles, and the heart all need to be checked before a general anesthetic, and patients with anti-MDA5 or anti-synthetase antibodies need particular care. Steroids, immunosuppressants, and IVIG require a written plan. Sun protection is part of treatment, lasers should be cautious and tested, fillers should favor what can be dissolved, and neurotoxins should stay away from the neck. Once the disease has been quiet for months, screening is clean, and the specialist agrees, many people with dermatomyositis can safely have the procedures they want. The right surgeon is the one who asks about the shoulders, the swallowing, and the screening before looking at the eyelids.